251. Nonviral gene delivery to the lung with copolymer-protected and transferrin-modified polyethylenimine.
Rudolph C, Schillinger U, Plank C, Gessner A, Nicklaus P, Müller R, Rosenecker J
Biochim Biophys Acta. 2002 Oct 10.
PMID: 12383945 [PubMed - in process]
252. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
Sato S, Kopitz C, Schmalix WA, Muehlenweg B, Kessler H, Schmitt M, Krüger A, Magdolen V
FEBS Lett. 2002 Sep 25.
PMID: 12297307 [PubMed - in process]
253. Immunomodulatory effects of the liver: deletion of activated CD4+ effector cells and suppression of IFN-gamma-producing cells after intravenous protein immunization.
Klugewitz K, Blumenthal-Barby F, Schrage A, Knolle PA, Hamann A, Crispe IN
J Immunol. 2002 Sep 1.
PMID: 12193708 [PubMed - in process]
254. O-(2-[(18)F]Fluoroethyl)- L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes.
Rau FC, Weber WA, Wester HJ, Herz M, Becker I, Krüger A, Schwaiger M, Senekowitsch-Schmidtke R
Eur J Nucl Med Mol Imaging. 2002 Aug .
PMID: 12173018 [PubMed - in process]
255. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA
Cancer Res. 2002 Aug 15.
PMID: 12183417 [PubMed - in process]
256. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo.
Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Krüger A, Gänsbacher B, Plank C
Gene Ther. 2002 Jan .
PMID: 11857068 [PubMed - in process]
257. Endothelial cell-mediated uptake of a hepatitis B virus: a new concept of liver targeting of hepatotropic microorganisms.
Breiner KM, Schaller H, Knolle PA
Hepatology. 2001 Oct .
PMID: 11584379 [PubMed - in process]
258. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M
Clin Cancer Res. 2001 Sep .
PMID: 11555589 [PubMed - in process]
259. Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells.
Knolle PA, Limmer A
Trends Immunol. 2001 Aug .
PMID: 11473832 [PubMed - in process]
260. Comparison of [18F]FHPG and [124/125I]FIAU for imaging herpes simplex virus type 1 thymidine kinase gene expression.
Brust P, Haubner R, Friedrich A, Scheunemann M, Anton M, Koufaki ON, Hauses M, Noll S, Noll B, Haberkorn U, Schackert G, Schackert HK, Avril N, Johannsen B
Eur J Nucl Med. 2001 Jun .
PMID: 11440032 [PubMed - in process]